Effect of a Plant-based Ingredient on Generalized Hormonal Responses
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Gieres, Frankrike
- Eurofins Optimed Clinical research
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Healthy males, Age at start of the study >20 and <50 years;
- Body mass index (BMI) ≥ 20,0 and ≤ 25,0 kg/m2;
- Apparently healthy: no medical conditions which might affect the study measurements, absorption, metabolism and distribution (including diabetes type 1 and type 2, gastrointestinal dysfunction, gastrointestinal surgery and inflammatory diseases);
- Fasting blood glucose value of subjects is ≥ 3.4 and ≤ 6.1 mmol/litre (i.e. 62-110 mg/dl) at screening;
- Agreeing to be informed about medically relevant personal test-results by a physician;
- Informed consent signed;
- Willing to comply to study protocol during study;
- Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research.
- Accessible veins on arms as determined by examination at screening.
Exclusion Criteria:
- Any history of diabetes, hyper- (or hypo-) glycemia or other disorder of glucose metabolism;
- Blood donation in the past 2 months;
- Reported participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study;
- Reported participation in night shift work two weeks prior to pre-study investigation or during the study. Night work is defined as working between midnight and 6.00 AM;
- Reported intense sporting activities > 10h/w;
- Consumption of > 21 alcoholic drinks in a typical week;
- Not being used to eat breakfast;
- Reported use of any nicotine containing products in the six months preceding the study and during the study itself;
- Use of medication which interferes with study measurements;
- Reported dietary habits: medically prescribed diet, slimming diet;
- Not used to eat 3 meals a day;
- Vegetarian;
- Reported weight loss/gain (>10%) in the last six month before the study;
- Being an employee of Unilever and CRO;
- Allergy or intolerance to food products and aversion to food products provided during the study;
- Subject who cannot be contacted in case of emergency;
- Subject who, in the judgment of the investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
- Subject under guardianship;
- Subject who would receive more than 4500 euro's as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Annen: Plant-based ingredient to a starchy meal
Plant-based ingredient
|
|
|
Annen: Starchy meal alone
No plant-based ingredient
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Amylin (total) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Ghrelin (active) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Glucose-dependent insulinotropic peptide (gastric inhibitory polypeptide, GIP) (total) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Glucagon-like peptide-1 (GLP-1) (active) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Leptin will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Pancreatic polypeptide (PP) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Peptide YY (PYY) (total) will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Insulin will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
C-peptide will be assessed.
|
120 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 120 minutes
|
Glucagon will be assessed.
|
120 minutes
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Amylin (total) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Ghrelin (active) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Glucose-dependent insulinotropic peptide (gastric inhibitory polypeptide, GIP) (total) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Pancreatic polypeptide (PP) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Peptide YY (PYY) (total) will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Leptin will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Glucagon will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Insulin will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
C-peptide will be assessed.
|
180 and 240 minutes
|
|
AUC of post-prandial hormones
Tidsramme: 180 and 240 minutes
|
Glucagon-like peptide-1 (GLP-1) (active) will be assessed.
|
180 and 240 minutes
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood glucose response (+iAUC)
Tidsramme: 120 and 180 minutes
|
Effect on blood glucose response.
|
120 and 180 minutes
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Yves DONAZZOLO, M.D., M.Sc., EUROFINS OPTIMED, GIERES - France
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
Andre studie-ID-numre
- FDS-NAA-1462
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .